HALEOS LABS LIMITED (HALEOSLABS) — Corporate Action | 29 May 2026

· NSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Haleos Labs Limited announced on May 29, 2026, that its board approved the audited FY2026 results and recommended a dividend of ₹1.501 per share, subject to shareholder approval at the upcoming AGM. The unmodified audit by Rambabu & Co. confirmed compliance with Ind AS and SEBI norms, while cash flow showed a net outflow of ₹5,789.64 lakhs due to heavy investing activities. Reappointments of directors and auditors were also ratified via e-voting.

📄 View Original Announcement (PDF)

About HALEOS LABS LIMITED (HALEOSLABS)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹460.98 Cr P/E: 29.2 ROE: 7.8% ROCE: 10.0% Div Yield: 0.10%

View full HALEOSLABS stock details →

📡 Get AI alerts when HALEOSLABS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track HALEOSLABS — Free

📊 More HALEOSLABS filings

See all HALEOSLABS filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when HALEOSLABS files new disclosures

Track HALEOSLABS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track HALEOSLABS — Free

Free account · 2 AI queries/day